Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...

NPPA notifies revised prices of certain products based on WPI increase: Gireesh Babu, New Delhi Saturday, March 29, 2025, 08:00 Hrs [IST] The National Pharmaceutical Pricing Autho ...

The new formula will replace EGRIFTA SV and treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.

Theratechnologies (THTX) stock gains as a new formulation of its best selling drug Egrifta is cleared by the FDA. Read more ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Theratechnologies (Nasdaq: THTX) has received approval from the US Food and Drug Administration for Egrifta WR (tesamorelin), ...